Cyclic adenosine 3',5'-monophosphate (cAMP) is an important second messenger which is involved in signalling pathways controlling cell proliferation and differentiation (Pastan et al., 1975; Prasad, 1975; Cho-Chung, 1980; Puck, 1987; Cho-Chung et al., 1990) . Cyclic AMP appears to exert its major effects through type A protein kinase (PKA), a tetrameric holoenzyme made up of two regulatory (R) and two catalytic (C) subunits. The protein kinase A regulatory subunits, also known as cAMP-binding proteins, may exist as different subtypes, which are referred to as the RI and RII isoforms. It has been suggested that levels and types of binding proteins may change during malignant transformation and may be associated with differences in tumour behaviour. For example, differential expression of the independent isoenzymes (RI or RII) may influence the regulation of tumour cell growth and differentiation phenotype (Tortora et al., 1990; Cho-Chung, 1990 ). Furthermore, levels of cAMP-binding proteins in rodent mammary carcinomas Bodwin et al., 1980; Cho-Chung et al., 1981) vary according to the degree of autonomy and growth status of the tumour. More recently, it has been reported that high levels of tumour cAMP-binding proteins are associated with poor prognosis in patients with breast cancer (Miller et al., 1990 (0, 0.005, 0.05, 5, 50, 50011M) . With respect to all other parameters, the binding assays were carried out as described previously.
Typing of cAMP-binding proteins using photoaffinity labelling Different types of binding proteins were determined by photoaffinity labelling with 8-azidoadenosine 3',5'-cyclic [32P]monophosphate. Cytosol samples (50 il) were prepared as described above and incubated with 8-N3-[32P]cAMP (151l), 15 ,sl of 0.27 M morpholine ethane sulphonic acid (Sigma) and 53 mM magnesium chloride in a 0.4 cm well microtitre plate at room temperature for 1 h in the dark. The contents of the wells were then UV irradiated for 30 s at 254 nm by placing a Mineralight UVS-1 1 hand lamp directly over the plate, as adapted from the method of Pomerantz et al. (1975) .
The reactions were stopped by the addition of sodium dodecyl sulphate (SDS) buffer (3% SDS, 15% 2-mercaptoethanol, 30mM Tris, 30% glycerol, 1% bromophenol blue). The samples were heated to 90°C for 3 min and the proteins resolved electrophoretically on a 12% SDS-PAGE gel for 3-4 h at 35 mA, according to the method of Laemmli (1970) . Radioactively labelled 14C molecular weight markers were run with each gel. After electrophoresis, the gels were fixed overnight in 40% methanol, 10% acetic acid, 10% glycerol, then dried under vacuum in a gel drier (Model 583-Biorad). The dried gels were then exposed to preflashed X-ray film (Kodak X-omat AR or Fuji) for 5-15 h at -80°C in autoradiography cassettes fitted with intensifier screens (Hispeed X-Genetic Research International). Autoradiograms were processed in Kodak X-ray developer and fixer.
Results

Assay conditions
To determine the effects of time and temperature on binding, tumour cytosols were incubated with [3H]cAMP in the absence and presence of 10,000 nM radioinert cAMP for varying times, either at room temperature or at 4°C. A typical result is shown in Figure 1 Figure 3a . Low concentrations of radioinert cAMP were able to compete with [3H]cAMP for binding, leaving only a low level of non-specific binding in the presence of a thousand-fold excess of competitor. The data plotted according to Scatchard (1949) showed that the dissociation constant of binding (KD) was about 10-8 M (Figure 3b ). Values in ovarian cancer cytosols Cytosols from 50 ovarian cancers were assayed for cAMPbinding proteins. The results are presented in Table I , and the concentrations of binding sites in individual tumours are plotted in Figure 5 . All tumours showed cAMP binding, but levels varied greatly between individual tumours, from 267 to 12,037 fmol per mg of cytosol protein and dissociation constants for binding ranged between 0.4 and 5.9 x 1-0 M.
Specificity of binding
Photoaffnity labelling of cAMP-binding proteins in ovarian tumour cytosols Tumour cytosols were labelled with 8-azidoadenosine 3',5'-cyclic [32P]monophosphate to identify the different types of cAMP-binding proteins present. Proteins of 52, 48, 43, 39 and 37 kilodaltons were identified in the cytosols, the proportion and pattern of which varied between the different tumour cytosols. To illustrate this, results from the first ten tumours examined are shown in Figure 6 and indicate, for example, that cytosols 1 and 6 predominantly express the 48 kDa protein, whereas cytosols 2 and 5 display the 52 kDa form.
Discussion
This is the first report of cAMP-binding protein measurements in human ovarian cancers. The study was prompted by work previously carried out on human breast cancers (Miller et al., 1990 ) indicating a link between levels of cAMP-binding proteins and eventual outcome of the disease. The results showed that high cAMP-binding protein levels are an indicator of poor prognosis. In contrast, in colorectal tumours low levels of binding appear to be associated with markers of poor prognosis such as advanced Dukes stage and poor histological grade (Bradbury et al., 1991) . As a prelude to an evaluation of the clinical utility of cAMP-binding measurements in ovarian cancer, the present paper describes the characterisation of an assay that may be used routinely to assess levels of binding protein in this tumour type. The method used involves incubating tumour cytosols with [3H]cAMP in the absence and presence of increasing concentrations of radioinert nucleotide. Maximum binding was observed at 4°C after a 24h incubation, and under these conditions binding was linearly correlated with cytosol protein concentration and appeared to be specific for cAMP and its analogues. It should be noted that these incubation conditions are different from those employed for breast cancers in other studies (3 h at room temperature). However, the present studies on ovarian cancer consistently demonstrate that incubation times beyond 2 h at room temperature are associated with decreases in activity. This may be an inherent effect due to decreased stability of the ovarian binding proteins or increased proteolytic degradation. Interestingly, at 4°C, plots of binding vs time invariably showed a transient dip in binding at around 90 min, and this suggests that the binding curve is composed of more than one component. This would be consistent with the results from photoaffinity labelling, which identified binding proteins differing in molecular weights.
Using the method as defined, cytosols of 50 human ovarian cancers were assayed for levels of cAMP-binding proteins. All possessed binding activity, levels varying from 267 to 12,037 fmol per mg of cytosol protein (mean value of 4248 fmol mg-'). These results fall within the range of human breast cancer cytosols reported by Miller et al. (1985) and are higher than those reported for a series of colorectal cancers using the same methodology. The mean dissociation constant of 2.4 X 10-8 M is also in keeping with data from previous work on human breast cancers (Miller et al., 1985) and work reported for binding proteins in other tumours .
Photoaffinity labelling of cAMP-binding proteins in the same ovarian cytosols displayed proteins with molecular weights of 52, 48 and 37 kDa similar to proteins that have been previously characterised in other tissues. Certain tumours also possessed binding proteins with molecular weight of either 43 or 39 kDa. The 48 and 52 kDa species probably correspond to the regulatory subunits of protein kinase A (RI and RII respectively), which have been characterised in different tissues (Eppenberger et al., 1980; Tortora et al., 1989; Bradbury et al., 1991; Miller et al., 1993) . The 37 kDa protein has been suggested to be a product resulting from proteolytic degradation of the regulatory subunits, and the relatively high levels of this protein are consistent with our suspicion that ovarian tumour cytosols are more. likely to display proteolytic activity than, for example, breast cancer. Although the identification of the binding proteins has not been completely defined, it is of interest that individual ovarian cancers may exhibit not only different levels of cAMP binding but also variations in patterns of binding. While the significance of differences in binding pattern is as yet unclear, it has been suggested that the RI and RII proteins differentially regulate systems which programme cellular proliferation and differentiation. It will thus be important to define the factors that influence both level and type of cAMP-binding protein within ovarian cancers, and these are the subject of continuing investigation. However, the obvious differences between individual ovarian cancers and our published work on breast cancer which suggests that these parameters are associated with differences in tumour behaviour and prognosis indicates that further research on the cAMP-dependent protein kinase A system in ovarian cancer is merited.
